In a population of cisgender men, transgender women, transgender men, and gender-nonbinary persons, the incidence of HIV is lower with receipt of twice-yearly subcutaneous lenacapavir.
The US journal "Science" has named the development of the drug Lenacapavir as this year's "Breakthrough of the Year". The ...
El Mundo on MSN10h
Drug that protects against HIV with two 'shots' a year, discovery of the year for 'Science'Lenacapavir, a treatment administered subcutaneously every six months, is capable of preventing infection with very high ...
But doing so still requires “substantial breakthroughs in synthetic cell research”, the scientists said. HIV gamechanger: Lenacapavir study participant explains Although the capability to engineer ...
The drug, named lenacapavir, targets the structure and function of HIV's capsid protein. It protects people for 6 months with each shot. Unlike mainstay HIV drugs that disrupt viral enzymes by binding ...
Science, a global scientific journal, has selected lenacapavir (lenacapavir), a groundbreaking HIV infection treatment, and related studies for the '2024 Innovation of the Year'. Renacapavir, an ...
That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...
That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...
The drug lenacapavir, developed by Gilead Sciences, provides protection for half a year instead of one day and has performed extremely well in clinical trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback